LFCR Stock Forecast & Price Target

Lifecore Biomedical is demonstrating a solid financial trajectory, with projected EBITDA increasing from $24.0 million in FY26, representing a 16.8% margin, to $27.3 million in FY27, which reflects a margin expansion to 19.1%. The company has recently turned positive in free cash flow, forecasting a rise from $5.1 million in FY26 to $6.0 million in FY27. Such improvements in both profitability margins and free cash flow position Lifecore Biomedical favorably for future growth and operational efficiency.

Lifecore Biomedical Inc. faces a negative outlook primarily due to its anticipated lack of meaningful revenue growth until calendar year 2027, which raises concerns about its long-term financial viability. Additionally, the company's high leverage ratio positions it unfavorably compared to peers, suggesting increased financial risk. Furthermore, while a 10% market growth figure for fill/finish services is considered reasonable, the expected overall market growth may be lower, further complicating the company's growth prospects.